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Long-term smartphone-based remote disease activity reporting is feasible in routine practice 








Dear Editor,  
 
We read with interest the recently published work by Lynn Austin and colleagues reporting 
the results of the REMORA study (1). We agree with the findings of the work and the robust 
methodology of the work that they undertook. In their conclusions Austin et al state “Patient 
engagement was strong throughout the 3 months, but it is unknown to what extent patients 
would continue to enter daily data over longer periods of time”. 
 
We have recently completed a twelve-month clinical pilot of a smartphone app in our 
rheumatology service in Bristol and report our experiences of offering a commercially 
available smartphone-based, cloud-enabled patient symptom diary to patients as part of a 
routine NHS rheumatology clinic over twelve-months. Our objectives were to: (i)  examine 
the proportion of patients within the rheumatology clinic who have access to technology 
allowing access to the service, (ii) identify the level of interest in such a service; (iii) examine 
the persistence and frequency of app use over time in the normal clinical environment; (iv) 
observe if longitudinal trends in disease activity could be identified at a patient-level. 
 
Patients with a clinical diagnosis of inflammatory arthritis attending routine rheumatology 
clinics were offered the opportunity to use a smartphone app (Living With Rheumatoid 
Arthritis™) to record their disease activity between hospital appointments. Patients who 
might be interested in using the app were identified by their treating clinician during their 
consultation. They had to have a smartphone (Android or iOS) and email address to be able 
to use the service and were given a verbal description of the download/installation process. 
Detailed download instructions and a hyperlink to the app were included in the invitation 
email. If requested, a postcard aide memoire with download/log in details was available.  
Patients were invited to complete a RAPID3 questionnaire on a weekly basis using their 
smartphone and received a pop-up reminder on their home-screen to submit their data. If no 
data was entered, a further reminder notification to their smartphone home screen was 
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issued. (2)  Data was stored locally on the smartphone and transferred to a secure cloud 
database portal which authorised clinicians could access using a web browser. Data were not 
used to alter access to rheumatology services. Patients were told that their data would only 
be reviewed during their consultations unless the clinical team were specifically asked to 
review the data between appointments. Patients were advised to let their clinician know 
during their consultation if they were using the app. Clinicians then viewed the data during 
the consultation via the clinical portal and data were used to enrich and facilitate history 
taking in consultations. No formal data were collected regarding clinician access or use of the 
data in clinics. Patient-level data could be viewed in graphical and tabular format via the 
clinical portal (Figure 1). 
 
To evaluate equity of access, we undertook a separate paper-based survey of patients 
attending routine rheumatology clinics which asked: “Do you have a smartphone or tablet 
device that can run ‘apps’?” and “Do you have an email address?”. Over a period of three 
weeks, unselected patients were given the survey in the waiting room and returned it to clinic 
support staff once completed.  
 
Data were collected on the number of patients invited to use the service, downloaded the 
app, number who actively used the app to record their disease activity and the RAPID3 scores 
over a twelve-month period from July 2018 to July 2019. Patients were recruited at any time 
during this twelve-month period, and so each had a variable length of time during which they 
were able to record data. 
  
Ethical approval was not required as this is was not a research study. The smartphone app is 
NHS Data Security and Protection Toolkit compliant (ODS Code 8JP33), adheres to GDPR 
regulations and institutional information governance approval was granted. 
 
54 patients were surveyed. The mean age was 54 years (range 17 - 86), 34 (70%) were female 
and 47 (87%) patients had a smartphone and email. Seven (13%) and three patients (6%) 
reported not having access to a smartphone or email respectively.  The mean age of patients 
with a smartphone and email address was 55 years, compared with 64 years for those 
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patients who did not have a smartphone, and 66 years for those who did not have an email 
address. 
 
141 patients were invited to use the app, 89 patients (63%) downloaded it, and 58 patients 
(41%) used it to record their disease activity. These patients had a mean age of 53 and were 
76% female. 35 patients had rheumatoid arthritis, 15 patients had psoriatic arthritis and 8 
had another inflammatory arthritis. 
 
Of the 58 patients who used the app at least once, the median number of RAPID3 scores 
completed per patient was 8 (interquartile range 3 – 17) with a median of 1 RAPID3 scores 
submitted per patient month (interquartile range 1 – 3). 53 of 58 patients had been enrolled 
for more than three months, and of these 43 (81%) continued to submit data after three 
months. Granular data of long-term user engagement over the year is shown in Figure 2. A 
total of 706 RAPID3 scores were submitted over the 12 months. The mean RAPID3 score was 
12 (range 0 – 27).  
 
This pilot demonstrates the feasibility of remote reporting of disease activity in routine 
practice. Most patients have the technology to participate and individual profiles of disease 
activity could help improve and expedite clinical history taking within the outpatient clinic 
and facilitate non-face-to-face interactions (Figure 1). After initial high non-uptake (37%), 
most patients (65%) that downloaded the app used it.  
 
This clinical pilot is important as it shows an appetite for such technology amongst 
rheumatology patients outside of the research setting. Research studies often have high user 
engagement, but are often of short duration and select a motivated group of patients, 
meaning translation of these data to the real-world clinical setting can be challenging.(1) 
Clinical pilots such as ours offer useful insights into the real-world use of these technologies. 
Use of the app in our pilot did not afford additional benefits for patients in terms of access to 
service, so our findings show that there is a genuine and persistent interest in using such 
technology without incentivisation. The next steps are to embed the technology to 
personalise outpatient experiences for patients and facilitate more efficient use of non-face-











 Figure 2. Kaplan-Meier curve demonstrating long term patient engagement with the app. Tick-marks represent censored 
data for patients who continued to use the app within one-month of the censor date of 27th July 2019. 95% confidence interval 
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